ScreenPoint Medical is proud to return to the European Congress of Radiology, held this year in Vienna, Austria from March 4–7. Join us at Booth D-16 (Expo Foyer D, Level -2) to explore how the Transpara® Breast AI Suite supports breast cancer screening through improved accuracy, workflow efficiency, and risk stratification.
ScreenPoint Medical’s presence offers radiologists and healthcare leaders the chance to learn, connect, and explore:
- Learn more about the Transpara® Breast AI Suite: ScreenPoint Medical will offer personalized demos of its best-in-class solutions: Detection, Density, and Temporal Comparison. These tools are designed to assist radiologists in identifying subtle malignancies and managing screening workloads.
- Scientific sessions offer key context: Backed by robust clinical evidence, Transpara Breast AI leads the competition and delivers for clients. Transpara is the subject of key sessions, including:
- MASAI RCT Results: Two sessions highlight the final research takeaways from the landmark MASAI randomised controlled trial, showing how Transpara helps radiologists focus on high-risk cases and reduces interval cancers. (Thursday, March 5 at 1630 CET, RPS-1102-1 and RPS-1102-2, M-Building, Research Stage 2)
- AIMS RCT Update: A discussion of the large-scale randomised trial evaluating Transpara-supported mammography in Norway. (Thursday, March 5 at 1630 CET, RPS-1102-3, M-Building, Research Stage 2)
- Risk Prediction: New research shows Transpara’s superior performance in five-year breast cancer risk prediction compared to traditional epidemiological models. (Friday, March 6 at 1230 CET, RPS-1402-7, M-Building, Research Stage 6)
- And many more.
- Expert Access: Co-founder and researcher Professor Nico Karssemeijer as well as VP of Clinical Innovation Alejandro Rodriguez-Ruíz will be on-site to discuss real-life cases, implementation strategies, and the latest research.
Our team looks forward to seeing you onsite and in person.
View all scientific sessions and schedule your personalized demo here.